

CD5 CAR

Antifungal off-the-shelf adoptive cell transfer immunotherapy

Novel adoptive CAR-NK cell transfer therapy in refractory invasive fungal infection

? CLINICAL NEED


Invasive fungal infections are a cause of high morbidity in immunocompromised patients (e.g., bone marrow transplant recipients, and cancer or ICU admitted patients). Moreover, there is an emergence of fungal infections multi-resistant to available antifungals, which are in turn costly and have significant associated toxicity. All this meaning that mortality in these cases can exceed 70%.

💡 SOLUTION

Off-the-shelf allogeneic CD5CAR NK cells for rapid adoptive cell transfer therapy overcoming antifungal drug resistance.

☀️ COMPETITIVE ADVANTAGE

No CAR-based cell therapies directed to fungal infections are clinically available. Our universal CAR-NK approach allows rapid treatment of immunosuppressed patients with invasive fungal infections refractory to antifungals.



🔒 INTELLECTUAL PROPERTY

Patent protection

Title: CAR-T/NK cells for use in the treatment of invasive fungal infections.

International Application Number: WO2023275402A1

📊 DEVELOPMENT

The CD5 CAR project is pending of AEMPS's (Spanish Agency for Medicinal and Sanitary Products) approval for initiation of clinical phase I trial set by first quarter of 2024.

🧩 LOOKING FOR

A partner to potentially license the technology and eager to develop a commercially available product.

👥 THE TEAM



Francisco Lozano MD PhD
Full Professor, Senior Consultant



Maria Velasco PhD
Researcher



CONTACT DETAILS

Knowledge and Technology
Transfer Office

innova@recerca.clinic.cat

jrivas@recerca.clinic.cat